Connection

JORGE CASTILLO to Antibodies, Monoclonal

This is a "connection" page, showing publications JORGE CASTILLO has written about Antibodies, Monoclonal.
Connection Strength

1.018
  1. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. Future Oncol. 2014 May; 10(7):1147-55.
    View in: PubMed
    Score: 0.297
  2. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011 Feb; 11(2):151-60.
    View in: PubMed
    Score: 0.237
  3. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
    View in: PubMed
    Score: 0.149
  4. Reducing treatment toxicity in Waldenstr?m macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
    View in: PubMed
    Score: 0.119
  5. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
    View in: PubMed
    Score: 0.108
  6. Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
    View in: PubMed
    Score: 0.078
  7. Consensus treatment recommendations from the tenth International Workshop for Waldenstr?m Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.